[go: up one dir, main page]
Skip to main content
Springer Nature Link
Log in

Tazemetostat: novel safety signals identified

  • Clinical study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+
from €37.37 /Month
  • Starting from 10 chapters or articles per month
  • Access and download chapters and articles from more than 300k books and 2,500 journals
  • Cancel anytime
View plans

Buy Now

Price includes VAT (France)

Instant access to the full article PDF.

Institutional subscriptions

Explore related subjects

Discover the latest articles, books and news in related subjects, suggested using machine learning.

Reference

  • Liu Q, et al. A Real-World Disproportionality Analysis of FDA Adverse Event Reporting System Events for Tazemetostat Therapeutic Innovation & Regulatory Science : 19 Aug 2025. Available from: URL: https://doi.org/10.1007/s43441-025-00845-4

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Tazemetostat: novel safety signals identified. Reactions Weekly 2075, 9 (2025). https://doi.org/10.1007/s40278-025-89225-2

Download citation

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1007/s40278-025-89225-2